EUVIMEDEUVIMED entdecken
Crossref

Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

Jose María Vieitez, Paula J. Fonseca, Jose P. Berros, Miguel Fernandez De Sanmamed, Eduardo Gutierrez Restrepo, Marta Izquierdo, Pablo Pardo, Angel J. Lacave

Cancer and Clinical Oncology · 2012

DOI: 10.5539/cco.v1n2p25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer and Clinical Oncology, 2012. Verfasst von Jose María Vieitez und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Zitieren

APA

Vieitez, J. M., Fonseca, P. J., Berros, J. P., Sanmamed, M. F. D., Restrepo, E. G., Izquierdo, M., Pardo, P., & Lacave, A. J. (2012). Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology. https://doi.org/10.5539/cco.v1n2p25

Vancouver

Vieitez JM, Fonseca PJ, Berros JP, Sanmamed MFD, Restrepo EG, Izquierdo M, et al. Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer. Cancer and Clinical Oncology. 2012. doi:10.5539/cco.v1n2p25

BibTeX
@article{Vieitez2012,
  author = {Vieitez, Jose María and Fonseca, Paula J. and Berros, Jose P. and Sanmamed, Miguel Fernandez De and Restrepo, Eduardo Gutierrez and Izquierdo, Marta and Pardo, Pablo and Lacave, Angel J.},
  title = {Irinotecan and Capecitabine (CAPIRI) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer},
  journal = {Cancer and Clinical Oncology},
  year = {2012},
  doi = {10.5539/cco.v1n2p25}
}
Kostenlos starten →